- Home
- FRA vs STRO Comparison
FRA vs STRO Comparison
Compare FRA & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRA | STRO |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | United States |
| Employees | N/A | 131 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.1M | 338.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FRA | STRO |
|---|---|---|
| Price | $10.59 | $24.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.38 |
| AVG Volume (30 Days) | ★ 180.9K | 167.1K |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | ★ 11.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.57 | $0.52 |
| 52 Week High | $13.41 | $27.96 |
Technical Indicators
Market Signals| Indicator | FRA | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 25.77 | 63.91 |
| Support Level | N/A | $0.76 |
| Resistance Level | $13.05 | $27.96 |
| Average True Range (ATR) | 0.15 | 2.27 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 7.69 | 63.15 |
Price Performance
Historical ComparisonAbout FRA Blackrock Floating Rate Income Strategies Fund Inc
Blackrock Floating Rate Inc Stra Fd Inc is a United States-based diversified closed-ended management investment company. The Fund's investment objective is to provide shareholders with high current income and preservation of capital with investment in a diversified, leveraged portfolio consisting of floating-rate debt securities and instruments.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.